Amongst sufferers with hormone receptor (HR)-positive, HER2-negative, high-risk early breast most cancers, postsurgical, or adjuvant, Verzenio (abemaciclib) plus endocrine remedy was related...
Amongst sufferers with PD-1/PD-L1-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), remedy with buparlisib and paclitaxel was not related to an...